Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2- Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT07599137
What this trial is testing

Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy

Who this might be right for
HR+/HER2- Breast Cancer
Peking University Cancer Hospital & Institute 86
Testing effectiveness (Phase 2)Study completedNCT07162051
What this trial is testing

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Xijing Hospital 28
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Early research (Phase 1)Looking for participantsNCT06139107
What this trial is testing

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Who this might be right for
Breast Cancer
Mridula George, MD 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005882
What this trial is testing

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Who this might be right for
Breast Cancer PatientsBreast Cancer Early Stage Breast Cancer (Stage 1-3)HR+/HER2- Breast Cancer+1 more
Azienda Ospedaliero-Universitaria Careggi 21
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Not applicableActive Not RecruitingNCT07710716
What this trial is testing

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,000
Testing effectiveness (Phase 2)Looking for participantsNCT07159451
What this trial is testing

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07292207
What this trial is testing

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Who this might be right for
ctDNA MonitoringBreast Cancer
Nagoya City University 30
Testing effectiveness (Phase 2)Looking for participantsNCT05708235
What this trial is testing

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Who this might be right for
Breast Cancer
MedSIR 976
Large-scale testing (Phase 3)Looking for participantsNCT07242352
What this trial is testing

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

Who this might be right for
Breast CancerHR+/HER2- Breast Cancer
Women's Cancer Study Group GmbH 1,520
Testing effectiveness (Phase 2)Active Not RecruitingNCT07130643
What this trial is testing

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

Who this might be right for
HR+/HER2- Breast Cancer
Xinhong Wu, PhD 40
Large-scale testing (Phase 3)Looking for participantsNCT06913777
What this trial is testing

Neoadjuvant SNF Precision Therapy Phase III

Who this might be right for
Neoadjuvant Therapy
Fudan University 404
Not applicableLooking for participantsNCT06830720
What this trial is testing

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 3,250
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Not applicableLooking for participantsNCT07215364
What this trial is testing

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

Who this might be right for
Early-stage Breast Cancer
Spanish Breast Cancer Research Group 74
Large-scale testing (Phase 3)Looking for participantsNCT05891093
What this trial is testing

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Who this might be right for
Breast Cancer
Fudan University 766
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Testing effectiveness (Phase 2)Looking for participantsNCT06970912
What this trial is testing

CtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more
Peking University People's Hospital 393
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06470633
What this trial is testing

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerHR+/HER2- Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 29
Next Page